Quick Answer
Oncology Institute, Inc. reported Total Revenue of $502.73 million for fiscal year 2025.
Oncology Institute, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $502.73M +27.8% |
$393.41M +21.3% |
$324.24M +28.4% |
$252.48M +24.4% |
$203.00M +8.3% |
$187.51M |
| Revenue (ASC 606) | $502.73M +27.8% |
$393.41M +21.3% |
$324.24M +28.4% |
$252.48M +24.4% |
$203.00M +8.3% |
$187.51M |
| Net Income | -$60.61M +6.3% |
-$64.66M +22.2% |
-$83.07M -54750.0% |
$152.0K +101.4% |
-$10.93M +23.7% |
-$14.32M |
| Diluted EPS | -$0.54 +23.9% |
-$0.71 +22.8% |
-$0.92 -338.1% |
-$0.21 -31.2% |
-$0.16 +33.3% |
-$0.24 |
| Total Assets | $164.66M -4.7% |
$172.72M -17.5% |
$209.24M -20.0% |
$261.67M +28.6% |
$203.44M +209.7% |
$65.69M +131278.0% |
| Long-Term Debt | $77.40M -16.9% |
$93.13M +7.3% |
$86.83M +7.7% |
$80.62M | $0.00 -100.0% |
$6.56M |
| Stockholders Equity | -$15.72M -538.0% |
$3.59M -93.7% |
$57.02M -53.7% |
$123.17M +18.3% |
$104.16M +270.7% |
$28.10M |
| Operating Income | -$36.08M +40.0% |
-$60.12M +21.9% |
-$77.02M +6.0% |
-$81.95M -78.7% |
-$45.86M -459.4% |
-$8.20M |
| Shares Outstanding | 98.86M +30.5% |
75.74M +2.1% |
74.15M +1.2% |
73.27M +0.0% |
73.25M +1173.9% |
5.75M +0.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $136.56M | +36.7% | +14.0% |
| Revenue (ASC 606) | September 30, 2025 | $136.56M | +36.7% | +14.0% |
| Net Income | September 30, 2025 | -$16.50M | -2.4% | +3.0% |
| Diluted EPS | September 30, 2025 | -$0.14 | +22.2% | +6.7% |
| Total Assets | September 30, 2025 | $163.62M | -8.7% | +2.4% |
| Long-Term Debt | September 30, 2025 | $76.19M | -16.8% | +1.6% |
| Stockholders Equity | September 30, 2025 | -$12.27M | -179.3% | -36.6% |
| Operating Income | September 30, 2025 | -$8.05M | +41.9% | +28.2% |
| Shares Outstanding | September 30, 2025 | 97.57M | +29.1% | +4.6% |
- Oncology Institute, Inc. reported Total Revenue of $502.73 million for fiscal year 2025.
- Oncology Institute, Inc. showed an increase of +27.8% in Total Revenue compared to the prior fiscal year.
- Oncology Institute, Inc. reported Revenue (ASC 606) of $502.73 million for fiscal year 2025.
- Oncology Institute, Inc. showed an increase of +27.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Oncology Institute, Inc. reported Net Income of -$60.61 million for fiscal year 2025.
- Oncology Institute, Inc. showed an increase of +6.3% in Net Income compared to the prior fiscal year.
- Oncology Institute, Inc. reported Diluted EPS of $0.54 per share (loss) for fiscal year 2025.
- Oncology Institute, Inc. showed an increase of +23.9% in Diluted EPS compared to the prior fiscal year.
- Oncology Institute, Inc. reported Total Assets of $164.66 million for fiscal year 2025.
- Oncology Institute, Inc. showed a decrease of -4.7% in Total Assets compared to the prior fiscal year.
- Oncology Institute, Inc. reported Long-Term Debt of $77.40 million for fiscal year 2025.
- Oncology Institute, Inc. showed a decrease of -16.9% in Long-Term Debt compared to the prior fiscal year.
- Oncology Institute, Inc. reported Stockholders Equity of -$15.72 million for fiscal year 2025.
- Oncology Institute, Inc. showed a decrease of -538.0% in Stockholders Equity compared to the prior fiscal year.
- Oncology Institute, Inc. reported Operating Income of -$36.08 million for fiscal year 2025.
- Oncology Institute, Inc. showed an increase of +40.0% in Operating Income compared to the prior fiscal year.
- Oncology Institute, Inc. reported Shares Outstanding of 98.86 million shares for fiscal year 2025.
- Oncology Institute, Inc. showed an increase of +30.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: